|
Experimental Models for Testing Novel Targets for Pancreatic Cancer Cell Invasion
|
1R21CA124931-01A1
|
$167,475
|
$167,475
|
MOUSA, SHAKER
|
ALBANY COLLEGE OF PHARMACY
|
|
RTOG Tissue Bank
|
5U24CA114734-04
|
$793,026
|
$79,303
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Molecular Target Focused Discovery of Anticancer Drugs
|
2R01CA090441-06A2
|
$381,250
|
$53,375
|
PETTIT, GEORGE
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Image-Guided System for Cancer Intervention
|
2R42CA115112-02A2
|
$591,060
|
$591,060
|
Vosburgh, Kirby
|
ASCENSION TECHNOLOGY CORPORATION
|
|
CellWell?: A microdevice for single cell analysis
|
7R21CA133551-02
|
$138,750
|
$138,750
|
NETTIKADAN, SAJU
|
ASPERA CORPORATION
|
|
PDX-1 is a Therapeutic Target for Pancreatic Cancer
|
2R01CA095731-06A1
|
$274,814
|
$274,814
|
BRUNICARDI, FRANCIS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Molecular Surgeon Symposium on Genetics and Genomics of Pancreatic Cancer
|
1R13CA132572-01
|
$5,000
|
$5,000
|
CHEN, CHANGYI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Tumor Suppressor Function of Smad4 by Ubiquitin
|
5R01CA108454-05
|
$224,756
|
$112,378
|
FENG, XIN-HUA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-02S1
|
$117,286
|
$2,346
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-02
|
$1,515,000
|
$30,300
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Regulation of p21waf1/cip1 by Rho and Ras signaling
|
5R01CA030721-06
|
$182,278
|
$72,911
|
OLSON, MICHAEL
|
BEATSON INSTITUTE FOR CANCER RESEARCH
|
|
The role of endothelial to mesenchymal transition (EndMT) in the tumor stroma
|
1K08CA129204-01A1
|
$135,270
|
$67,635
|
ZEISBERG, ELISABETH
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Metabolic Syndrome as Pancreatic Cancer Etiology
|
1R21CA127794-01A2
|
$191,250
|
$191,250
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A Novel Biotherapeutic Treatment for Pancreatic Cancer
|
1R43CA117283-01A2
|
$99,965
|
$99,965
|
Xu, Kevin
|
BEXION PHARMACEUTICALS, INC.
|
|
CellWell?: A microdevice for single cell analysis
|
1R21CA133551-01
|
$30,000
|
$30,000
|
NETTIKADAN, SAJU
|
BIOFORCE NANOSCIENCES, INC.
|
|
Cancer Cluster Morphology
|
2R44CA112743-02
|
$375,414
|
$262,790
|
Jacquez, Geoffrey
|
BIOMEDWARE
|
|
NADPH oxidase and pancreatic cancer cell survival
|
5R01CA119025-03
|
$72,009
|
$72,009
|
GUKOVSKAYA, ANNA
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
Biomarkers and Therapeutic Targets in Pancreatic Cancer
|
5R01CA114103-04
|
$287,037
|
$287,037
|
WHANG, EDWARD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Lineage Tracy in Murine Pancreatic Cancer Metastasis
|
5F32CA123887-03
|
$45,048
|
$45,048
|
FRESE, KRISTOPHER
|
CAMBRIDGE RESEARCH INSTITUTE (CRUK)
|
|
Lineage Tracy in Murine Pancreatic Cancer Metastasis
|
5F32CA123887-03X1
|
$7,000
|
$7,000
|
FRESE, KRISTOPHER
|
CAMBRIDGE RESEARCH INSTITUTE (CRUK)
|
|
Pre-Clinical Evaluation of Novel Therapeutics for PDA
|
5F32CA123939-03
|
$43,428
|
$43,428
|
Olive, Kenneth
|
CAMBRIDGE RESEARCH INSTITUTE (CRUK)
|
|
Pre-Clinical Evaluation of Novel Therapeutics for PDA
|
5F32CA123939-03X1
|
$7,000
|
$7,000
|
Olive, Kenneth
|
CAMBRIDGE RESEARCH INSTITUTE (CRUK)
|
|
Mutant mouse models of exocrine pancreatic cancer
|
5R01CA101973-05
|
$209,928
|
$209,928
|
Tuveson, David
|
CAMBRIDGE RESEARCH INSTITUTE (CRUK)
|
|
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
|
2U01CA062502-15
|
$751,074
|
$7,511
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-18S3
|
$234,254
|
$4,685
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-19S1
|
$72,416
|
$1,448
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-19S2
|
|
$0
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-19
|
$5,104,000
|
$102,080
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Role of menin in islet cell biology and tumorigenesis
|
5K22CA103843-03
|
$155,250
|
$108,675
|
Scacheri, Peter
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Normal Cellular Prion Protein in Pancreatic Cancer
|
1R21CA133559-01
|
$245,963
|
$245,963
|
SY, MAN-SUN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Multi-Center Study of Pancreatic Cancer Etiology
|
5R01CA102765-05
|
$1,070,318
|
$1,070,318
|
MANDELSON, MARGARET
|
CENTER FOR HEALTH STUDIES
|
|
Collagen XV as a tumor and metastasis suppressor.
|
5R21CA129258-02
|
$152,611
|
$152,611
|
HARRIS, ANN
|
CHILDREN'S MEMORIAL HOSPITAL (CHICAGO)
|
|
Transforming growth factor beta signaling pathways
|
5R01CA055536-17
|
$308,158
|
$77,040
|
HOWE, PHILIP
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
An integrative approach to cancer gene discovery in hepatocellular carcinoma
|
5R01CA124648-02
|
$419,084
|
$41,908
|
POWERS, SCOTT
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL CANCER CENTER SUPPORT GRANT
|
5P30CA045508-22
|
$4,126,879
|
$41,269
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
Cancer Center Support Grant
|
2P30CA013696-35
|
$3,785,244
|
$113,557
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
PTEN Tumor Suppressor and Signal Transduction
|
5R01CA082783-08
|
$241,297
|
$120,649
|
Parsons, Ramon
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The tumor-suppressive role of ALK4/ACVR1B in pancreatic tumorigenesis
|
1R21CA127701-01A2
|
$217,350
|
$217,350
|
SU, GLORIA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
|
5R01CA109525-05
|
$250,358
|
$250,358
|
SU, GLORIA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Minimally-Invasive Image-Guided Therapy for Cancer Treatment
|
1R41CA128130-01A2
|
$149,562
|
$149,562
|
LU, ZHENG-RONG
|
CONTRADYN, INC.
|
|
Detection and Diagnosis of Pancreatic Cancer
|
5R01CA096924-04
|
$241,362
|
$241,362
|
GOLD, DAVID
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
|
Chemotherapy of Pancreatic Cancer: Induction of Apoptosis or Senescence
|
1R21CA123313-01A2
|
$249,885
|
$249,885
|
MODRAK, DAVID
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
|
Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
|
5R01CA115755-03
|
$319,025
|
$319,025
|
SHARKEY, ROBERT
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S1
|
$124,531
|
$3,736
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S2
|
|
$0
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S3
|
$49,998
|
$1,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S4
|
$143,383
|
$4,301
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S5
|
|
$0
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-44
|
$11,641,774
|
$349,253
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
BAD Intergrates Glycolysis and Apoptosis
|
5K01CA106596-05
|
$158,490
|
$158,490
|
DANIAL, NIKA
|
DANA-FARBER CANCER INSTITUTE
|
Total relevant funding to Pancreas for this search: $87,277,150
|